1. Home
  2. AEVA vs STTK Comparison

AEVA vs STTK Comparison

Compare AEVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$13.14

Market Cap

600.2M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.34

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
STTK
Founded
2019
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AEVA
STTK
Price
$13.14
$3.34
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
$26.50
$4.00
AVG Volume (30 Days)
2.0M
424.7K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,154,000.00
$1,000,000.00
Revenue This Year
$87.44
N/A
Revenue Next Year
$70.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
89.90
N/A
52 Week Low
$2.52
$0.69
52 Week High
$38.80
$3.38

Technical Indicators

Market Signals
Indicator
AEVA
STTK
Relative Strength Index (RSI) 47.15 72.67
Support Level $12.83 $2.82
Resistance Level $15.73 $3.29
Average True Range (ATR) 1.24 0.23
MACD -0.11 0.00
Stochastic Oscillator 6.67 94.64

Price Performance

Historical Comparison
AEVA
STTK

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: